protein extracts from normal or tumor ovaries as reported previously [6] . Hens were monitored for 45 weeks by α v β 3 -integrins targeted CE-US imaging at 15 week intervals. Sera from all hens were collected at each scan and stored at -80 0 C .
α v β 3 -integrins targeted contrast enhanced ultrasound (CE-US) imaging:
Scanning of hens and analysis of sonograms were performed similar to Specific Aim 1 which is briefly mentioned below: Pre-contrast scanning: Sonography was performed in a continuous pattern before and after the injection of contrast agent with the mechanical set up reported previously [7] . Briefly, all hens were scanned using an instrument equipped with a 5-to 7.5-MHz endovaginal transducer (MicroMaxx; SonoSite, Inc, Bothell, WA). Each hen was immobilized, the transducer was inserted (transvaginally), and a 2-dimensional transvaginal gray scale sonography as well as a pulsed Doppler sonography was performed. The resistive index (RI: [systolic velocity -diastolic velocity]/systolic velocity) and the pulsatility index (PI: [systolic velocity -diastolic velocity]/mean) were automatically calculated from at least 2 separate images from the same ovary, and the lower RI and PI values were used for analysis. All images were processed and digitally archived. Post-contrast Scanning Post-contrast injection scanning was performed in a similar and continuous manner with identical mechanical settings as described above and the same pre-contrast imaged area was imaged according to the instruction of the manufacturer of the contrast agent and the earlier report [8] . Within 5-7 min from the arrival of the contrast agent, it accumulated at the target sites and unbound free microbubbles were washed out. All images were archived digitally in a still format as well as real-time clips (15 minutes for each hen). The effect of the contrast agent was evaluated visually during the examination and afterward from reviewing the archived still images and video clips. The time of the contrast agent arrival (interval in seconds from administration of the contrast agent to its visual observation [in seconds]) in the normal and tumor ovaries was recorded in real time. After review of the complete clip, the region of interest (ROI) was selected. The average image intensity over a ROI encompassing the tumor was calculated and normalized by the pre-contrast intensity of the same ROI. The pixel intensity of ROI predictive of OVCA was determined. In addition, post-contrast RI and PI were calculated.
Result: On gray scale sonography at initial scan, healthy hens with low egg laying rates (n = 20 selected hens) showed one or two large preovulatory and several small growing follicles in the ovarian stroma. Blood vessels were detected in the ovarian stroma on color Doppler ultrasound imaging. Overall, similar to previous observation, compared with pre-contrast, the pixel intensity of the signals from the ovary increased significantly after the injection of the contrast agent. No detectable changes or abnormalities in ovarian morphology were observed in any of the experimental hens by targeted imaging at the 1 st interval (15 weeks after initial scan). However, at the 2 nd interval (30 weeks from initial scan) tumor related changes were suspected in 2 of 20 old hens with low egg laying rates. These morphological changes included a small solid tissue mass-like appearance limited to a part of the ovary with little or no ascitic fluid. Sonograms of these hens were processed and analyzed off-line immediately to determine the signal intensities in pixel values from the ROIs (consisting of the area suspected to have a solid mass) of the images. All of these hens had signal intensities above the pixel values indicative of tumor established in Specific Aim 1. These hens were euthanized and processed for subsequent tissue and molecular studies mentioned later. Figure 1 shows representative ultrasound images of an ovary before and after the injection of α v β 3 -integrins targeted contrast agent (B-mode, showing tumor size and borders). Post-contrast imaging predicted to have a small solid mass. At 3 rd scan (45 weeks from the initial scan), 6 of the remaining 18 hens were diagnosed with ovarian tumor related changes. These 6 hens together with the remaining 12 hens with apparently normal ovaries were euthanized at the end of the 45 weeks. Thus, compared to pre-contrast scans, targeted imaging by α v β 3 -integrins targeted contrast agent enhanced Hens were monitored prospectively by α v β 3 -integrins targeted ultrasound imaging at 15 week intervals. RI values in hens (that developed tumors later) reduced consistently (P <0.001) from 1 st scan to 3 rd scan at the time of OVCA diagnosis (left panel, an imaginary dotted line shows the gradual reduction). Reduced RI values indicate lower resistance causing the increases flow of blood to the tissue, a characteristics feature associated with tumor development. Similar patterns of changes were also observed for PI values. However, such consistent changes in RI values were not observed in hens remaining normal. Bars with different letters indicate significant differences within the same group. visualization of solid masses in the ovaries of 8 hens on gray scale. All hens that developed ovarian tumors later showed a consistent decrease in RI and PI values even before the tumor become detectable (Figure 2) . The post-contrast RI and PI values for all of these hens with detectable solid ovarian mass were <0.44and <0.96, respectively as determined in Specific Aim 1. All hens with RI values less than 0.44 were predicted to have ovarian TAN based on their ovarian vascularity as depicted by Doppler ultrasound scan following the targeted imaging.
Gross and histopathologic evaluation
All hens suspected of ovarian tumors and those remaining apparently normal during scanning by α v β 3 -integrins targeted contrast agent at different intervals including the final one at the end of the 45-weeks of prospective monitoring were euthanized. Gross ovarian morphology and stages of OVCA were recorded, normal ovaries and ovaries with tumor were harvested and processed for histopathological and immunohistochemical studies (paraffin and frozen), proteomic and molecular biological studies. Ovarian tumors, their stages, and types were confirmed by routine histologic examination with hematoxylin-eosin staining (Figure 3A-B) . Predictions of targeted imaging were compared and confirmed by gross examination of hens at necropsy and from routine histology. As observed on sonography, ovarian tumors (n = 8 hens) were limited to the ovary (3 serous, 4 endometrioid, and 1 mucinous) with little or no ascites. 
Association of serum prevalence of anti-NMP antibodies and DR6 levels with the development and progression of ovarian tumors:
Blood from all hens was collected prior to ultrasound scanning and serum samples in aliquots were stored at -80 0 C until further use. Serum samples were used in immunoassay for the detection of anti-NMP antibodies and DR6 as well as in immunoproteomics for confirming the immunoreactivities of serum against the ovarian tumor NMPs. Prevalence of anti-NMP antibodies in serum: The nucleus of the cell has long been used in the pathological diagnosis of cancer. Tumor associated changes in the molecular and morphological features of the nucleus represent the earliest event leading to malignant differentiation of the cell. Enlargement in size and irregular shape of the nucleus, re-organization of the chromatin and modifications in the composition of the nuclear matrix (which organizes the chromatin within the nucleus) are changes associated with malignant nuclear transformation. These morphological changes lead to the shedding or release of nuclear matrix proteins (NMPs) into the circulation eliciting an autoimmune response producing anti-NMP antibodies. Anti-NMP antibodies are well established markers for several human autoimmune diseases and are associated with carcinoma of several organs.
Circulating anti-NMP antibodies were detected as reported previously with a little modification [6] . 96-well immunoassay plates were coated with tumor NMPs from hens with OVCA, overnight blocked and incubated with serum from normal or hens with OVCA for two hours followed by rabbit anti-chicken alkaline phosphatase conjugated second antibodies for one hour. Immunoreaction was developed using alkaline phosphates substrate and plates were read at 405nm and optical density (OD) values were recorded. 5 young laying hens with normal egg laying rates were used as controls. Mean OD + 3SD of control hens were used as cut-off values. Hens with OD values greater than the Ovarian section from a hen at early stage OVCA (containing a small tumor mass limited to a part of the ovary) and positive serum anti-NMP antibodies. Compared to normal, the nuclei increased in size and changed in shape (irregular) during malignant transformation. The nuclei become pleomorphic with mitotic bodies. H&E, 100X. Figure 6 . Changes in nuclear size during malignant cellular transformation in the ovary of hens. Nuclear area is expressed as mean + SD in μm 2 (n =8). Compared with normal ovarian surface epithelium, the nuclear area of malignant cells was significantly (P<0.01) greater in hens with early stage OVCA (n =8) than in normal hens. (n = 8). Bars with different letters indicate significant differences. cut-off value were considered as positive for circulating anti-NMP antibodies. At the 1 st interval (15 weeks after initial scan), 3 of 20 hens were found positive and additional 4 hens were positive at the 2 nd interval (30 weeks after initial scan) and 4 of remaining 13 hens were positive for anti-NMP antibodies at the final scan (45 th weeks after the initial scan). Thus a total of 11 of 20 hens had anti-NMP antibodies in their serum at the end of 45 week of monitoring. Once a hen became positive for anti-NMP antibodies it remained positive for subsequent intervals. All hens with OVCA were positive for serum anti-NMP antibodies. Immuno-proteomic analysis (two-dimensional Western blotting) using representative sera positive for anti-NMP antibodies showed specific immunoreactivity of tumor sera against tumor NMPs (Figure 4) .
Changes in nuclear morphology are shown in Figure 5 . Nuclear areas in normal or malignant cells were counted from 5 random fields at 100X in section stained with hematoxylin and eosin. The Mean (+SD) area (expressed in μm 2 ) of the 5 largest nuclei were counted from a 100X light microscopic, filed and the mean of 5 fields were considered as the mean area of the nucleus in a normal or malignant ovarian section. The average of 3 sections from the same ovary was considered as the mean area of the nucleus of a hen with or without OVCA. 8 hens with OVCA (3 serous, 4 endometrioid and 1 mucinous) and 8 normal hens were used for nuclear morphometric analysis. As compared with the mean area of the nuclei in normal hens, the mean area of the nuclei was significantly greater in hens with OVCA or hens positive for serum anti-NMP antibodies ( Figure 6) . A nuclear morphological index (NMI) = nuclear area (NA) in (OVCA hens)/ (NA in control hens) was determined and a cut-off value (>2X NA of normal hens) was found diagnostic of OVCA based on tumor histopathology. These results suggest that malignant nuclear transformation is associated with the prevalence of anti-tumor antibodies in serum.
Association of DR6 levels with ovarian tumor development:
Death receptor (DR) 6 is a member of the tumor necrosis factor super family receptor associated with the induction of apoptosis under normal conditions. In contrast, apoptosis in ovarian tumors is reduced although DR6 expression is remarkably higher than in normal ovaries. DR6 is expressed in tumor cells and in the endothelium of tumor microvessels and is associated with malignant progression in human OVCA. DR6 has been reported to be expressed in the laying hen ovary and shown to induce apoptosis in granulosa and theca cells of ovarian follicles. Importantly, the expression of DR6 by reproductive tissues that exhibit increased physiological angiogenesis, such as placenta, corpus luteum, or proliferative endometrium are significantly less as compared with tumor tissues.
DR6 levels in the sera of normal or OVCA hens were determined by immunoassay using anti-chicken DR6 antibodies. Hens with optical density (OD) values for serum DR6 level greater than a cut-off value established in Specific Aim 1 (mean OD of normal hens + 3SD, 3.02 + 0.06 X 3=3.20) were considered to have OVCA. Hens with OD values for serum DR6 levels greater than the cut-off value were considered to have ovarian tumor associated neo-angiogenesis (TAN). All hens predicted to have ovarian tumors or ovarian TAN by the CE-DUS imaging had OD values for DR6 higher than the OVCA diagnostic level established in Aim 1 (mean + SD = 3.02 + 0.06 X 3=3.20). Immunoreactivity of DR6 proteins was confirmed by immunoblotting using selected serum samples. These results suggest that the development of ovarian tumors is associated with an increase in serum levels of DR6.
Tissue expression of markers of ovarian tumor associated neoangiogenesis (TAN):
Expression of α v β 3 -integrins and DR6 by normal ovaries and ovaries with tumor was determined by immunohistochemistry using anti-DR6 and anti-α v β 3 integrins antibodies. Immunopositive microvessels or cells were counted as reported previously [9] .
Expression of α v β 3 -integrins: α v β 3 -integrins were expressed by the endothelium of the immature and leaky angiogenic microvessels and localized at the tumor vicinity (spaces between tumor glands) (Figure 7) with occasional expression by ovarian epithelia. Compared to normal hens (Figure 7A) , the frequencies of α v β 3 -integrin expressing microvessels were significantly (P<0.05) greater in hens with early stage OVCA (mean + SD= 5.84 + 1.66 in 20,000μm 2 of tumor tissue) than normal hens (2.92 + 0.90 in 20,000μm 2 of ovarian stromal tissue) ( Figure 7B) . These results confirm that the greater signal intensities from hens with suspected ovarian tumor mass observed in the molecular targeted CE-US imaging suggest that ovarian tumor associated microvessels express α v β 3 -integrins which can be detected in vivo and may be used as an imaging marker for the detection of OVCA at the early stage.
Tissue expression of DR6: Malignant ovarian tumor epithelium in OVCA hens as well as angiogenic microvessels was positive for DR6 expression (Figure 8) . In normal ovaries, few microvessels in the follicular theca and in the stroma showed immunoreactivities for DR6 (2.81 + 0.56 in 20,000μm 2 of ovarian stromal tissue) while many DR6+ microvessels were localized in hens with early stage OVCA (mean + SD= 6.44 + 0.66 in 20,000μm 2 of tumor tissue, P<0.05) (Figure 9 The numbers of immunopositive microvessels are expressed as mean + SD. Compared with normal hens (n = 11), the number of α v β 3 -integrins and DR6 expressing microvessels was significantly (P <0.01) greater in OVCA hens (n= 8) than normal hens. Bars with different letters indicate significant differences. Figure 8 . Immunohistochemical detection of DR6 expression in normal ovaries or ovaries with tumor. Sections were immunostained with anti-chicken DR6 antibodies. A-B) DR6 expression by microvessels in the stroma of a normal ovary (A) or ovary with tumor at early stage (B) in hens. Compared with norrmal ovary (A), more DR6 expressing microvessels are seen in the stroma of the ovaries with early stage OVCA (B). C-D) DR6 expression by ovarian malignant epithelial cells. Very few normal ovarian surface epithelium expressed DR6 (C). Compared with normal, strong immunoreaction was detected in malignant epithelium (D). Arrows indicate the examples of immunopositive microvessels or epithelial cells. F = stromal follicle, TG = tumor gland, TS = tumor stroma, 40X. vessels in normal and tumor hens, respectively) were evaluated for the detectability of ovarian TAN. TANI for normal ovary was considered as 2 (1 for α v β 3 -integrins and 1 for DR-6 expressing vessels). Values of TANI from all hens at early stage OVCA were greater than normal hens (4.30 vs 2, P <0.01).
As a whole, Specific Aim 2 showed that (1) serum anti-NMP antibodies appear before the tumor becomes detectable by targeted ultrasound imaging, positively correlated with the malignant nuclear transformation and ovarian TAN; (2) Serum prevalence of anti-NMP antibodies is correlated with the serum levels of DR6 detective of OVCA or ovarian TAN.
KEY RESEARCH ACCOMPLISHMENTS:
The key research accomplishments during the reporting period are:
Established that ovarian tumor associated anti-NMP antibodies appear in serum before the tumor becomes detectable by targeted ultrasound imaging;
Serum anti-NMP antibodies are an indicator of ovarian malignant nuclear transformation;
Prevalence of serum anti-NMP antibodies is associated with the increase in serum DR6 levels detective of OVCA; 
Manuscript in preparation:
One manuscript is being submitted
CONCLUSION:
The results of the accomplishments of Aim 1 and Aim 2 suggest that contrast enhanced molecular imaging targeting ovarian α v β 3 -integrins can detect ovarian tumor associated neo-angiogenesis at early stage ovarian cancer in the laying hen model of spontaneous ovarian cancer. Changes in early stage ovarian cancer related CE-US imaging indices were associated with the elevation of serum levels of death receptor (DR6). Serum prevalence of anti-NMP antibodies is associated with tumor development and progression. Anti-NMP antibodies appear in serum before the tumor become detectable through imagining. Thus serum anti-NMP antibodies may be used as a surrogate marker of ovarian malignant nuclear transformation.
Expression of Death Receptor 6 by Ovarian Tumors in Laying
Hens, a Preclinical Model of Spontaneous Ovarian Cancer 1
Introduction
Ovarian cancer (OVCA) is the most lethal tumor among gynecologic malignancies, with an estimated yearly incidence rates of 22,000 in the United States and 42,000 in Europe [1, 2] . In most cases, OVCA is detected at advanced stages, and despite the remarkable improvements in treatment strategies, most of these patients have recurrences. The reasons for failure to detect and treat OVCA at an early stage as well as its high rate of recurrences are the lack of an effective early detection test, suppression of antitumor immunity by the tumor, and resistance to drugs [3] [4] [5] . OVCA differs from other malignancies in its specific dissemination pattern, which is characterized by tumor spread in a diffuse intrapelvic and abdominal manner [5] . Thus, the local tumor microenvironment including tumor-associated neoangiogenesis and suppression of antitumor immunity play important roles in the development and progression of ovarian tumors. However, the way tumor establishes neoangiogenesis and escapes antitumor immune surveillance is not well understood. Information on factors related to the development of tumor-associated angiogenesis and immune suppression in the tumor microenvironment is important because it may offer opportunities to establish an early detection test as well as targeted antitumor therapy. Death receptor 6 (DR6) has been suggested to be one of such factors because of its expression by blood vessels and its involvement in immunoregulation [6, 7] . DR6 is a member of the tumor necrosis factor α receptor superfamily (TNFRSF21) [8, 9] . Although DR6 has been shown to be involved in apoptotic cell death, elevated expression of DR6 has been observed in several tumors in humans [10] . DR6 expression was increased in tumor tissues from patients with late-stage prostate and breast cancers compared with its level in normal tissues [10] . Recently, DR6 concentration in the serum has been shown to be elevated in patients with late-stage OVCA [6] . In addition, DR6 has been demonstrated to be expressed by blood vessels in tumor tissues [11] . All these reports suggest that increased DR6 expression is associated with advanced stages of several malignancies including OVCA. However, its association with early-stage OVCA including tumor-associated angiogenesis is not known.
Suppression of antitumor immunity has been suggested as one of the mechanisms of tumor survival and progression [5] . Despite the presentation of antigens by malignant cells, which should induce immune-mediated rejection, spontaneous rejection of established tumor is rare [5] . Inefficient tumor rejection by the immune system is not only a passive result of insufficient effector cells [12, 13] because tumors induce immune-suppressive mechanisms that protect them against eradication [3, 4] . Compared with other solid tumors, studies on immunosuppression by ovarian tumors are very few. As in other epithelial malignancies, antitumor immune responses were reported to be elicited against ovarian tumors [14] [15] [16] , but these responses were not effective enough to eliminate bulky tumor [5] . Moreover, the distinctive type of disease dissemination (peritoneal spread and metastasis) makes OVCA unique compared to other solid tumors. Although the precise mechanism(s) of inadequate or defective antitumor immune responses are not well understood, expression or secretion of immunosuppressive factors by the tumor has been suggested as a potential strategy for immune evasion. DR6 has been reported to alter normal differentiation of monocyte to immature dendritic cells rather than mature dendritic cells [17] and immature dendritic cells have been demonstrated to induce tolerance [18] . Furthermore, because of its inhibitory roles in T-and B-cell proliferation and migration, DR6 has been proposed to be immunosuppressive and may be involved in tumor cell survival and immune evasion [7] . However, expression of DR6 by ovarian tumors at early stages as well as inhibition of antitumor immunity by DR6 in OVCA patients is not known.
To develop and improve the efficacy of an antitumor immunotherapy, more insight into the interaction between ovarian cancer (OVCA) and the immune system is needed. Information on DR6 expression by ovarian tumors may lead to the identification of additional targets, which may allow opportunities for developing new therapeutic approaches to inhibit tumor progression. Studies on the immune response against tumors or immune suppression by ovarian tumors at early stages are lacking. Furthermore, if DR6 is expressed by ovarian tumor-associated neoangiogenic microvessels, it may be a useful target for the early detection of OVCA by Doppler ultrasound imaging. The difficulty in identifying patients with OVCA at an early stage and the limited access to tumor tissue are significant barriers to the study and to the development of an effective immunotherapy against OVCA. Laying hens are the only widely available and easily accessible animals that develop OVCA spontaneously with high incidence rates and remarkably similar histologic subtypes and tumor markers to human OVCA [19] [20] [21] . In addition, avian DR6 has been reported to be orthologous to human DR6 (70% homology) and is expressed by the hen ovaries [22] . Thus, the objective of the present study was to explore whether DR6 is expressed by ovarian tumors in hens and, if so, whether its expression changes in association with the stage of the tumors and histologic subtypes.
Materials and Methods

Animals
A flock of 3-year-old commercial strains of White Leghorn laying hens (Gallus domesticus) was maintained under standard poultry husbandry practices. Hens (n = 120) were selected based on their egg laying rates (normal or low) and transvaginal ultrasound scanning as reported previously [23] . The incidence of OVCA in hens of this age group is approximately 15% to 20% and is associated with low or complete cessation of egg laying [19, 23] . All experimental procedures were performed according to the institutional animal care and use committeeapproved protocol.
Tissue Collection and Processing
Serum samples. Blood was obtained from brachial veins of all hens before euthanasia and centrifuged (1000g for 20 minutes), and serum samples were stored at −80°C.
Ovarian morphology and histopathology. Ovarian pathology and tumor staging were performed by gross and histologic examination as reported previously [19] . Each normal and malignant ovary (tumor bearing ovary) was divided into four portions for protein extraction, total RNA collection, paraffin and frozen embedding for routine histology, and immunohistochemical studies as reported previously [24] . Normal ovarian surface epithelial (OSE) cells or tumor cells (malignant epithelial cells of the tumor) in hens with OVCA were collected as reported earlier [25, 26] . Samples were divided into three groups including normal and early-and late-stage OVCA based on gross inspection and microscopy as previously reported [19] .
Preparation of Ovarian Specimen for Biochemical Analysis
Snap-frozen ovarian tissues as well as normal OSE cells and tumor cells from hens with normal ovaries or hens with OVCA were homogenized with a Polytron homogenizer (Brinkman Instruments, Westbury, NY) as reported previously [27] , were centrifuged; the supernatant was collected and the protein content of the extract was measured and stored at −80°C.
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Immunohistochemistry
Rabbit polyclonal anti-chicken DR6 antibodies were used as primary antibodies, and immunoreactions were determined using Vectastain Elite ABC kit (Universal, RTU; Vector Laboratories, Inc, Burlingame, CA). Normal or malignant ovaries (n = 15 hens each for normal, early, and late stages) were selected randomly for immunohistochemical study. The number of hens for each group for immunohistochemistry was determined based on the power analysis to achieve significant differences in different parameters among the normal or malignant groups. Briefly, after deparaffinization, antigens on the sections were unmasked by heat treatment, endogenous peroxidase in the sections was inactivated, and nonspecific staining was blocked by incubating with 0.3% hydrogen peroxide in methanol and normal horse serum, respectively. Sections were then incubated for 2 hours with primary antibodies (1:100 dilution) followed by 1 hour of incubation with secondary antibodies (Vectastain Elite ABC kit; Vector Laboratories). Immune reaction products on the sections were visualized by incubating with diaminobenzidine and hydrogen peroxide mixture (DAB Peroxidase Substrate Kit, 3,3′-diaminobenzidine; Vector Laboratories). Sections were then counterstained with hematoxylin, dehydrated, and covered. Control staining was carried out simultaneously in which the first antibodies were omitted and normal serum was used. No staining was found in these control slides.
Sections were then examined under a light microscope attached to digital imaging software (MicroSuite version 5; Olympus Corporation, Tokyo, Japan). The population of microvessels expressing DR6 as well as the intensity of DR6 staining by the normal ovarian stroma or stroma (around the tumor) in malignant ovaries was determined. Three sections per ovary and five regions of interest with the highest immunoreactivity (20,000 μm 2 per region at an objective of ×40 and ocular magnification of ×10) per section were selected. Using the software, the intensity of the DR6 immunostaining in each region was measured and recorded as pixel values in 20,000 μm 2 of the section as reported previously [28] . The mean of pixel values of these five regions in a section was considered as the intensity of DR6 in a 20,000-μm 2 area of each section. The mean intensity of three sections was considered as the DR6 staining intensity in a 20,000-μm 2 area of each normal or malignant ovary. The groupwise DR6 staining intensity (normal or tumor groups) was expressed as mean ± SD in a 20,000-μm 2 area of ovaries in normal or malignant groups. Similarly, and using the same software, the population of microvessels expressing DR6 in the section was counted and reported as the frequency (mean ± SD) of DR6expressing microvessels in a 20,000-μm 2 area of the stroma of normal or malignant ovaries as reported previously [29] .
One-dimensional Western Blot
Ovarian expression of DR6 was confirmed by immunoblot analysis using homogenates of normal (n = 5) or malignant ovaries as well as normal OSE cells or tumor cells. Twelve samples (four from each of the serous, endometrioid, and mucinous samples) at early and late stages of OVCA were selected for immunoblot analysis based on their immunoreactivity for DR6 in immunohistochemistry. Immunoreactions on the membrane were visualized as a chemiluminescence product (Super Dura West substrate; Pierce/Thermo Fisher, Rockford, IL), and the image was captured using a Chemidoc XRS (Bio-Rad, Hercules, CA). Similarly, serum samples from the same hens used for ovarian DR6 expression were selected for immunoblot analysis to examine the presence of DR6 in serum. Serum samples were filtered by acetonitrile and chloroformmethanol precipitation before using for immunoblot analysis [27] .
Reverse Transcription-Polymerase Chain Reaction
DR6 mRNA expression was assessed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) as reported previously [30] . For RT-PCR analyses, serum and tissue samples from 5 hens with normal ovaries, from 12 hens with early stages of OVCA (4 for each histologic subtype), and from 12 hens with late stages of OVCA (4 for each histologic subtype) were selected based on their reactivity in immunohistochemistry and immunoblot analysis. Hen-specific DR6 primers were designed by OligoPerfect Designer software (Invitrogen, Carlsbad, CA) using the DR6 sequence from the National Center for Biotechnology Information (accession no. A1980074) as reported earlier [22] . The forward primer was 5′-GAT GGA GGA CAC CAC GCC-3′ and the reverse primer was 5′-TCG GGG TTG AGG ATG TGC-3′. β-Actin was used as the endogenous control, with a forward primer of Laying hens ovulate and subsequently lay eggs once a day for 5 or 6 days in a week in a continuous manner and then take a pause for 1 day before laying resumes. Thus, the ovary in a fully functional laying hen contains a set of multiple large and growing preovulatory follicles arranged in a hierarchy of sizes (F1-F5). The largest follicle (F1) is destined to ovulate soon and then the second largest follicle (F2) becomes F1 and a small growing follicle is recruited from the ovarian stroma to the hierarchy to maintain the laying rates. (B) Ovarian tumor at an early stage in a hen showing solid tumor mass (arrows) limited to the ovary. (C) Ovarian tumor at a late stage. The tumor (Tu) appears like a cauliflower and has metastasized to other organs with accompanied profuse ascites (*).
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DR6 Expression in Ovarian Tumors Barua et al. Translational Oncology Vol. 5, No. 4, 2012 TGCGTGACATCAAGGAGAAG and a reverse primer of ATGC-CAGGGTACATTGTGGT. The expected base pair size for the DR6 amplicon was 384 bp and that for β-actin was 300 bp. PCR amplicons were visualized in a 3% agarose gel (Pierce/Thermo Fisher) in Tris-acetate-EDTA (TAE) buffer and stained with ethidium bromide. The image was captured using a ChemiDoc XRS system (Bio-Rad).
Statistical Analysis
The differences in the intensity of DR6 immunostaining and the number of microvessels expressing DR6 in normal ovaries and malignant ovaries were assessed by analysis of variance, F tests, and the alternative nonparametric Kruskal-Wallis tests. Subsequently, pairwise comparison between the groups (normal and early-and late-stage OVCAs) by two-sample t tests and alternative Mann-Whitney tests were performed. All reported P values are two-sided, and P < .05 was considered significant. Statistical analyses were performed with SPSS (PASW) version 18 software (IBM, Inc, Armonk, NY).
Results
Ovarian Morphology
In laying hens, only the left ovary becomes functional, and the rate of egg production declines with aging. A fully functional ovary contains five to six developing large preovulatory follicles ( Figure 1A ). As the hen ages, the rate of egg production decreases. The ovary of an older (>3 years old) healthy hen with a low rate of egg production contains fewer than three large preovulatory follicles. In apparently healthy hens that have stopped laying eggs, the ovaries were atrophied and the oviducts were smaller. Solid tissue masses either limited to a small part or the entire ovary, with or without ascites, were observed in 12 hens. These hens were diagnosed with early-stage OVCA ( Figure 1B ). In 16 hens, tumor had metastasized to the abdominal organs with moderate to profuse ascites. These hens were diagnosed with late-stage OVCA ( Figure 1C ).
Histopathology. Cortical follicles with or without distinguishable granulosa cell and theca layer were embedded in the ovarian stroma of hens with normal ovaries (Figure 2A ). Tumors were confirmed in all hens displaying gross ovarian solid masses (12 hens at early stage with solid masses limited to the ovaries or in 16 hens with late-stage OVCA) by routine histology (Figure 2 , B-D). However, tumor-related microscopic changes (including focal lesions containing large cells with irregular shapes and pleomorphic nuclei) were also found during histologic examinations in 11 additional hens that had no gross ovarian tumor and were grouped in early-stage OVCA. Thus, a total of 23 (12 + 11) hens had early-stage OVCA, 16 had late-stage OVCA, whereas 81 hens had normal ovaries. Tumors were typed as serous (n = 17), endometrioid (n = 12), mucinous (n = 8), clear cell (n = 1), as well as mixed (n = 1, seromucinous) as reported previously [19] .
Tissue Expression of DR6
Microvessels expressing DR6 were detected in both normal and malignant ovaries ( Figure 3 ). Most of the DR6-expressing ovarian Translational Oncology Vol. 5, No. 4, 2012 DR6 Expression in Ovarian Tumors Barua et al.
microvessels in hens with normal ovaries had thick, complete, and continuous vessel walls with intense staining. These vessels were located in the theca layer of the follicles and a few vessels were in the ovarian stroma. In contrast, most of the DR6-expressing vessels in malignant ovaries were discontinuous or incomplete with thin vessel walls ( Figure 3A ). The number of DR6-expressing microvessels was significantly higher (P < .01, exact Mann-Whitney test) in hens with early (mean ± SD = 8.0 ± 2.29 microvessels per 20,000-μm 2 area of stroma) and late (13.0 ± 2.37 microvessels per 20,000-μm 2 area of stroma in malignant ovaries) stages of OVCA than in hens with normal ovaries (3.0 ± 0.52 microvessels per 20,000-μm 2 area of stroma in normal ovaries; Figure 3B ). However, significant differences in the population of DR6-expressing microvessels among the histologic subtypes were not observed. Tumor cells ( Figure 4A ) as well as a few normal OSE cells expressed DR6. In addition, rounded (T lymphocyte like) to irregularly shaped (macrophage-like) DR6 cells were also detected in the stroma of the normal ovaries or malignant ovaries. Compared with normal ovaries (mean ± SD = 3.6 × 10 6 ± 3.8 × 10 5 in a 20,000-μm 2 area), the intensities of DR6 staining increased approximately 9-fold (P < .001) in hens with early-stage OVCA and 13-fold (P < .001) in hens with late-stage OVCA, respectively ( Figure 4B ). However, significant differences in DR6 staining intensities were not observed among three different histologic subtypes of OVCA in hens. The frequency of microvessels expressing DR6 in a 20,000-μm 2 area of normal (n = 15) and malignant ovaries (expressed as the mean ± SD, n = 15 each for early and late stages). Compared to the normal ovary, the frequency of microvessels expressing DR6 was significantly (P < .001) higher in hens with early-stage OVCA cancer and increased further (P < .001) as the disease progressed to a late stage in hens. Each bar with a different letter indicates significant differences (P < .001) between normal and tumor groups.
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DR6 Expression in Ovarian Tumors Barua et al. Translational Oncology Vol. 5, No. 4, 2012 Immunoblot analysis for DR6 protein in ovarian tissues and serum samples. Immunohistochemical expression of DR6 in normal or malignant ovaries was confirmed by immunoblot analysis using homogenates of OSE cells (from normal ovaries) or tumor cells (from malignant ovaries) as well as homogenates from whole normal or malignant ovaries. A band of 50 to 60 kDa was detected in the homogenates of cells (normal OSE cells or tumor cells) and tissues (whole normal or tumor ovaries; Figure 5A ). In addition, immunoreactive 50-to 60-kDa DR6 protein was also detected by immunoblot analysis in the serum of hens with normal ovaries or those with OVCA ( Figure 5A ). Compared with the whole ovarian homogenates or serum from hens with normal ovaries, immunoreactivity for DR6 protein was intense in the homogenates of malignant ovaries or serum from hens with OVCA ( Figure 5A ). These results support the immunohistochemical observation that OSE in hens with normal ovaries and tumor cells in hens with OVCA express DR6 protein. Moreover, these epithelial cells may be a source of DR6 proteins in the circulation of laying hens because DR6 was detected in the serum of hens with normal ovaries or those with OVCA.
Expression of DR6 messenger RNA. DR6 messenger RNA (mRNA) expression confirmed the observed variations in ovarian DR6 expression among hens with normal ovaries or those with OVCA. Although the patterns of DR6 mRNA expression were similar between normal OSE and tumor cells from early-stage OVCA, it was stronger for tumor cells from late-stage OVCA. Compared with the hens with normal ovaries, strong amplification of signal for DR6 ( Figure 5B ) was observed in the ovarian extracts from hens with earlystage OVCA and the amplification was stronger in hens with latestage OVCA. However, differences in DR6 mRNA expression were 
Discussion
This is the first report on the expression of death receptor (DR6) by tumor cells of malignant ovaries in hens. The expression of DR6 was significantly higher in the tumor cells of malignant ovaries than OSE cells of normal ovaries. Furthermore, the population of ovarian microvessels expressing DR6 was significantly higher in hens with early-stage OVCA than hens with normal ovaries and increased further in hens with late-stage OVCA. In addition, DR6 was also detected in the serum of hens. Thus, the results of the present study suggest that the increase in DR6 expression may be associated with ovarian tumor development and progression in laying hens. Tumor-associated neoangiogenesis (TAN) and suppression of antitumor immunity are two of the early events required for the survival and progression of the tumor. Increased numbers of immature microvessels with disorganized and discontinuous smooth muscle layers are the characteristic features of ovarian TAN in patients as well as in laying hens with OVCA [24] . Compared to hens with normal ovaries, the number of DR6-expressing microvessels was significantly higher in hens with early-stage OVCA and increased further in hens with late-stage OVCA. A recent study has reported increased expression of DR6 by ovarian tumors in patients with advanced-stage OVCA [6] . In this study, the population of DR6-expressing ovarian microvessels increased significantly at an earlier stage even before the tumor became grossly detectable. Recently, DR6 was reported to be required for angiogenesis in the central nervous system [31] . Although precise reason(s) for the increase in the population of DR6-expressing microvessels in malignant ovaries is not known, it is possible that DR6 will play a role in the development of ovarian TAN.
Despite the presence of an antitumor immune response [5, 32] , the rare eradication of ovarian tumors and their progression suggest that multiple mechanisms are used by the tumor to escape immune rejection. The expression of DR6 has been reported to be increased significantly in cell lines and patients with prostate and breast cancers [7, 10, 33] . In the absence of DR6, ligation of the T-cell receptor results in enhanced T-cell proliferation, activation, and skewed T H 2 cytokine production. Similarly, B cells lacking DR6 show increased proliferation, cell division, and cell survival on mitogenic stimulation (anti-CD40 and LPS) or BCR ligation. DR6−/− mice showed increased T H 2 immune responses to both T-dependent and -independent antigens. In contrast, it is suggested that increased DR6 expression on tumor cells results in the cleaving of extracellular part of DR6 from the cell surface by matrix metalloproteinase 14. This shed DR6 reported to attenuate the in vitro differentiation of monocytes into immunotolerant instead of immunocompetent dendritic cells, which can contribute to tumor evasion from the immune system [17] . All these reports indicate that DR6 plays important roles in imparting tolerance to local immune response. In the present study, the expression of ovarian DR6 was significantly high in hens with early-stage OVCA than in hens with normal ovaries and increased further in hens with late-stage OVCA. Although the significance of increased DR6 expression by malignant cells is not known, the results of the current study suggest that increased DR6 expression may play important roles in the suppression of immunity against ovarian tumors.
The results of the current study suggest several translational significances. Because the malignant tumors in hens express DR6 and it is also present in the serum, DR6 could be targeted for contrast-enhanced ultrasound imaging to detect the tumor. Thus, use of DR6-expressing epithelium in the ovary as a target may increase the sensitivity of ultrasound scanning to detect OVCA together with serum levels of DR6. Hence, it will bring a significant change in imaging paradigms and improve the specificity of ultrasound scanning. It will also make possible to determine the time between the tumor-associated elevation of DR6 in serum and the earliest detection of tumor by contrast-enhanced ultrasound scanning. This information will enable the detection of OVCA at an early stage and lead to the development of treatment modalities for patients with OVCA. In addition, current findings will also be useful in developing ovarian tumor-associated anti-DR6 therapies, which can be tested in laying hens. Taken together, information on the association of DR6 with the early detection of OVCA and the potential development of anti-DR6-based therapies will establish the foundation for clinical studies. It may thus ultimately lead to the development of an effective diagnostic test and therapies for OVCA at an early stage.
In conclusion, this study showed that the tissue expression of DR6, a potential tumor-associated neoangiogenic and immunosuppressive factor, was significantly higher in hens with early-stage OVCA than in hens with normal ovaries and increased further as the disease progressed to late stages. This information will be useful and contribute to clinical studies to determine the role of DR6 in OVCA development and progression in humans. 
Expression of Leukocyte
Introduction
Despite the remarkable improvements in cytoreductive surgeries and chemotherapeutics, ovarian cancer (OVCA) remains one of the most lethal gynecologic malignancies of women with a high death rate [1] . Owing to the lack of an effective early detection test, OVCA in most cases is detected at late stages, and its high recurrence rate (80%-90%) contributes to poor prognosis [2, 3] . There is an emerging recognition that tumor growth, in general, elicits specific immune responses mediated by cell-mediated immunity [4] . As a result, immunotherapies against several cancers are being developed [4] [5] [6] . Although recent advances in immunotherapy have been shown to improve the overall survival ability of patients with hematologic tumors and melanoma [7] , most immunotherapeutic trials have failed to demonstrate success in clinical responses [6, 8] . Thus, development of new strategies to promote immune responses against malignancies is critical in overcoming the limited efficacy of conventional therapies. Despite the presentation of antigens by ovarian malignant cells, which should induce immune-mediated rejection, spontaneous rejection of an established tumor is rare [9] . This lack of immune response is not only because of the ignorance of the immune system but also because of the tumor-induced immune suppression that protects the tumor from eradication [9] . Therefore, a better understanding of the mechanisms of tumor-induced immunosuppression will enhance our ability to prevent ovarian tumor progression and to design antitumor interventional strategies.
Numerous studies on cancers of several organs have reported several mechanisms of tumor-induced immune suppression including induction of regulatory T cells [10] , expression of immunosuppressive factors (transforming growth factor β, interleukin 10, and chemokine ligand 22) [10] [11] [12] , down-regulation of intracellular adhesion molecules [13] , and induction of peripheral tolerance [4, 14, 15] . In contrast, studies on the mechanism of immune suppression in ovarian malignancy are very limited. OVCA differs from other malignancies in its specific dissemination pattern [9] . The tumor typically spreads in a diffuse intra-abdominal fashion rather than through systemic circulation. Thus, antitumor immune response at the tumor environment plays a critical role to ovarian tumor metastasis. Immunosuppressive regulatory T cells [10] , transforming growth factor β [11, 12] , tolerance-inducing plasmacytoid dendritic cells [16] , B7-H4+ macrophages [17] , and interleukin 10 [18] have been reported to be present in the tumor microenvironment. However, how these immunosuppressive factors and agents are recruited into the tumor environment is not known. Emerging studies suggest that induction of inhibitory receptor immunoglobulin (Ig)-like transcript 3 (ILT3) expression is one of the mechanisms contributing to the tumor-induced immune suppression in several malignancies [19] .
ILT3 is a member of leukocyte Ig-like receptors family with inhibitory functions and exists in both membrane and soluble forms [20] . Both forms of ILT3s have been suggested to inhibit T-cell proliferation, CD4 + T-cell anergy, suppressing the differentiation of interferon γ-producing CD8 + cytotoxic lymphocytes. In addition, membrane and soluble ILT3 were also reported to stimulate the differentiation of regulatory T cells in various cancer patients [4, 5, 10] . All these findings suggest that ILT3 may be involved in the immunosuppression against tumor antigens and prevention or blocking of ILT3 expression may enhance a patient's immune responses to malignancies. The expression of ILT3 in OVCA patients has not yet been reported. Difficulties in identifying and access to patients at the early stage of OVCA hinder the ability to study the involvement of ILT3 in OVCA progression and develop interventional strategies for its prevention. Rodents do not develop OVCA spontaneously, and the histopathologies of induced OVCA in rodents do not resemble the spontaneous OVCA in humans [21] . Recently, we have shown that laying hens are the only widely available animals that develop OVCA spontaneously with a high incidence rate and histopathologies remarkably similar to human OVCA [22] . The expression of leukocyte Ig-like receptors has been reported in chicken, which are shown to be orthologus to those of mammals including humans [23, 24] . Thus, the goal of this study was to examine whether ILT3 is expressed in ovarian tumors in the laying hen model of spontaneous OVCA and, if so, whether ILT3 expression is associated with the progression of ovarian tumors in hens.
Materials and Methods
Animals
Commercial strains of approximately 3-year-old white Leghorn laying hens (Gallus domesticus) were selected from a flock of layers maintained under standard poultry husbandry practices. The incidence of OVCA in hens of this age group is approximately 15% to 20% and is associated with low or complete cessation of egg laying [25] . Hens (n = 148) were selected on the basis of their egg-laying rates (normal, low, or ceased egg laying) and transvaginal ultrasound scanning as reported previously [25] . All experimental procedures were performed according to the institutional animal care and use committee approved protocol.
Tissue Collection and Processing
Serum samples. Blood was obtained from brachial veins of all hens before euthanasia, centrifuged (1000g for 20 minutes), and serum samples were stored at −80°C until further use.
Gross ovarian morphology and histopathology. Ovarian pathology and tumor staging were performed by gross and histologic examination as reported previously [22] . Each normal ovary or ovary with tumor was divided into four portions for protein extraction, total RNA collection, paraffin and frozen embedding for routine histology, and immunohistochemical studies as reported previously [26] . Ovarian surface epithelial (OSE) cells from normal or ovaries with tumor were collected similarly as reported earlier [27] . All collected samples were grouped into three groups including normal-, early-, and late-stage OVCA based on the diagnosis of the histopathologic ovarian tissue examination as reported previously [22] .
Preparation of Ovarian Specimen for Biochemical Analysis
Snap-frozen normal ovaries and ovaries with tumor as well as OSE from normal ovaries and ovaries with tumor were homogenized with a Polytron homogenizer (Brinkman Instruments, Westbury, NY) as reported previously [28] and centrifuged, the supernatant was collected, and the protein content of the extract was measured and stored at −80°C until further use.
Histopathologic Examination and Immunohistochemistry
Paraffin or frozen sections from each ovary with tumor or ovaries that appeared normal without any grossly detectable tumor were stained with hematoxylin and eosin and observed under a light microscope. Presence or absence of tumors in the section and their histologic types were determined as reported earlier [22] . Immunohistochemical detection of ILT3 expression was performed using goat anti-ILT3 (R&D Systems, Inc, Minneapolis, MN) as primary antibodies (n = 15 hens each, for normal, early, and late stages as reported previously) [26] . The number of hens for each group was determined based on statistical power analysis to achieve significant differences in the intensities of ILT3 immunostaining among the hens of normal or OVCA groups. These hens were selected from each group randomly. Briefly, sections were deparaffinized, and antigens on the sections were unmasked by heating the sections with an antigen-unmasking solution (Vector Laboratories, Burlingame, CA) for 20 minutes in a microwave oven. Endogenous peroxidase in the sections was inactivated, and nonspecific staining was blocked by incubating with 0.3% hydrogen peroxide in methanol for 30 minutes followed by 1% (vol/vol) normal horse serum for 15 minutes, respectively. Sections were then incubated overnight with primary antibodies (1:100 dilution) followed by 1 hour of incubation with anti-goat IgG-HRP secondary antibodies (R&D Systems). Immunoprecipitates on the sections were visualized by incubation with a mixture of diaminobenzidine and hydrogen peroxide in diaminobenzidine buffer (Vector Laboratories). Sections were then counterstained with hematoxylin, dehydrated, and covered. Control staining was carried out simultaneously in which the first antibodies were omitted and normal goat serum was used. No staining was found in these control slides. Sections were then examined under a light microscope attached to digital imaging software (MicroSuite version 5; Olympus Corporation, Tokyo, Japan). Three sections per ovary and five regions of interest (20,000 μm 2 /region at ×40 objective and ×10 ocular magnification) per section were randomly selected. Using the software, the intensity of the ILT3 immunostaining in each region was measured and recorded as pixel values in 20,000 μm 2 of the section. The mean of pixel values of these five regions in a section was considered as the intensity of each section, and the mean of intensities of three sections was considered as the mean of ILT3 staining intensity in normal or tumorbearing ovaries.
One-dimensional Western Blot
The expression of ILT3 proteins by normal ovaries or ovarian tumors as well as OSE from normal ovaries or ovaries with tumor was determined by Western blot analysis using primary and secondary antibodies mentioned above. On the basis of immunohistochemical staining results, representative samples of ovarian as well as OSE homogenates from normal or ovarian tumors at early and late stages were used in immunoblot analysis. Immunoreactions on the membrane were visualized as a chemiluminescence product (Super Dura West substrate; Pierce/ Thermo Fisher, Rockford, IL), and the image was captured using a Chemidoc XRS (Bio-Rad, Hercules, CA). Digital images obtained with Chemidoc XRS were analyzed by Quantity One software (Bio-Rad) according to the manufacturer's recommendation, and the intensities of immunoreactive bands were expressed as density per intensity in squared millimeter and the mean of intensities for each normal or pathologic group as well as for the stages of OVCA were calculated. No immune reaction was observed in controls where protein samples were omitted. Serum samples for Western blot analysis were selected similar to ovarian samples and tested to confirm the presence of soluble ILT3.
Reverse Transcription-Polymerase Chain Reaction
ILT3 messenger RNA (mRNA) expression in ovarian tissues or epithelial cells from normal hens or hens with OVCA was assessed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) as reported previously [29] . Representative samples of normal ovaries or ovaries with tumor as well as OSE from hens were selected for RT-PCR analyses based on their immunoreactivities in immunohistochemistry and immunoblot analysis were used. Henspecific ILT3 primers were designed by Oligoperfect Designer software (Invitrogen, Carlsbad, CA) using the ILT3 sequence from the National Center for Biotechnology Information (GenBank: NM_001146134.1). The forward primer was 5-TGG CTG TAC CAG GAA AGA GG and the reverse primer was 5-CTC TGA TGC CCC TAC TGA CC. β-Actin was used as the endogenous control with a forward primer of TGCGTGACATCAAGGAGAAG and a reverse primer of ATGC-CAGGGTACATTGTGGT. The expected base pair size for the ILT3 amplicon was 150 bp and that for β-actin was 300 bp. PCR amplicons were visualized in a 3% agarose gel (Pierce) in TAE buffer and stained with ethidium bromide, and images were captured using a ChemiDoc XRS system (Bio-Rad). PCR products were sequenced, and the sequence was the same as the sequence of primers from the National Center for Biotechnology Information GenBank (NM_001146134.1).
Statistical Analysis
The differences in the pixel intensities of ILT3 immunostaining among different histologic subtypes and stages (early vs late) were assessed by two-way analysis of variance. This was followed by pairwise comparison between the histologic subtypes (normal, endometrioid, mucinous, and serous) within each stage and comparison of the stages within histologic subtypes by two-sample t tests and alternative Mann-Whitney tests. All reported P values are 2-sided, and P < .05 was considered significant. Statistical analyses were performed with SPSS (PASW) version 18 software (IBM, Inc, Armonk, NY ) and R statistical software.
Results
Morphologic and Histologic Features of Hen Ovaries and Ovarian Tumors
Gross morphology. A fully functional ovary in a healthy laying hen contained five to six developing large preovulatory follicles ( Figure 1A) , whereas the ovaries of low-laying healthy hens contained less than three preovulatory follicles. In normal hens that had stopped egg laying, ovaries and oviducts were regressed without any detectable abnormality. Solid tissue masses either limited to a small part or to the whole ovary and with or without ascites were observed in 14 hens and classified as hens with early-stage OVCA ( Figure 1B) . In 17 hens, the tumor had metastasized to abdominal organs with moderate to profuse ascites and classified as hens with late-stage OVCA (Figure 1 , C and D).
Histopathology. A total of 105 hens were found to have normal ovaries in which embedded primordial and primary follicles were observed in the ovarian stromal tissue (Figure 2A ). Ovarian tumors were confirmed by routine histology in 31 hens that had solid masses limited to the ovaries (n = 14, early stage) or metastasized to other organs (n = 17, late stage). In addition, microscopic OVCAs were detected in 12 hens without any grossly detectable solid mass in the ovary and grouped in early-stage OVCA. Thus, a total of 26 (14 + 12) hens had early and 17 had late-stage OVCA. Tumors were typed (Figure 2 , B-D) as serous (n = 18), endometrioid (n = 13), mucinous (n = 10), as well as mixed (n = 2, seromucinous and endoserous) as reported previously [22] .
Tissue Expression of ILT3
Immunohistochemical detection of ovarian ILT3 expression.
T-lymphocyte-like rounded cells and macrophage-like irregularshaped cells in the stroma of normal ovaries or ovaries with tumor were found positive for ILT3. Some surface epithelial cells (not all) above the developing cortical follicles in normal ovaries and the epithelium of the ovarian tumors were also stained positive for ILT3 expression (Figure 3, A-D) . The expression of ILT3 by the epithelial cells of the tumor in hens with OVCA varied with respect to the histologic subtypes of tumors and their stages. As compared with normal hens (mean ± SD = 23029.23 ± 2725.01), the intensities of ILT3 expression were significantly higher (P < .001) in hens with early-stage OVCA irrespective of their histologic subtypes (Figure 4 ). Similar patterns were also observed for hens with late-stage OVCA. Among different histologic subtypes at early-stage OVCA, the intensities of ILT3 staining were lowest in hens with ovarian endometrioid tumors (mean ± SD = 36,807.56 ± 2843.56) followed by mucinous (40,207.86 ± 2858.27) and highest in serous OVCA (40,924.40 ± 1400.26) in a 20,000-μm 2 area of tissue (Figure 4 ). The differences in ILT3 staining intensities were significantly higher in hens with serous OVCA than hens with endometrioid OVCA irrespective of their stages (P < .028 and .025 for early and late stages of OVCA, respectively). However, significant differences in ILT3 staining intensities were not observed between the hens with ovarian endometrioid and mucinous OVCA as well as mucinous and serous OVCA at early and late stages. In hens with serous OVCA, the intensities of ILT3 staining were significantly high in late stages than in early stage (P < .05). However, a significant difference in ILT3 staining intensities between the early and late stages of hens with ovarian endometrioid or mucinous OVCA was not observed.
Immunoblot analysis for ILT3 protein in ovarian tissues and serum samples. Immunohistochemical observation of ILT3 expression was
confirmed by immunoblot analysis using homogenates of normal ovaries and ovaries with tumors as well as OSE from normal ovaries and ovarian tumors. As expected, immunoreactive ILT3 protein with a band size of approximately 55 kDa was detected in the homogenates of OSE and ovarian tissues from normal hens and hens with OVCA at early stage ( Figure 5A ). Similar patterns were also observed for serum Figure 5A) . Conversely, the expression of immunoreactive ILT3 proteins was weaker in the homogenates of ovarian endometrioid tumors, moderate in mucinous, and stronger in ovarian serous tumors at the early stage ( Figure 5A ). Similar patterns were also observed for ovarian tumors at late stage (data not shown). These results confirm the immunohistochemical observation that epithelial cells of ovarian tumors in hens express ILT3.
Expression of ILT3 mRNA. Observed variations in ILT3 protein expression among different histologic subtypes of OVCA and their stages were confirmed by ILT3 mRNA expression. Hens with early serous and mucinous ovarian tumors showed strong amplification signal for ILT3, whereas its amplification was low for endometrioid ovarian tumors. However, no differences were observed for ILT3 mRNA expression by different histologic subtypes of late-stage OVCA ( Figure 5B ). Similar patterns were also observed for the epithelial cells of ovarian tumors. Thus, the results of gene expression study confirm the immunohistochemical and immunoblot analysis observations that the epithelium of ovarian tumors expresses ILT3 proteins.
Discussion
This is the first report on the expression of ILT3 by the epithelium of ovarian tumors in laying hens, an animal model of spontaneous OVCA. This study showed that the expression of ILT3 increases significantly in association with ovarian tumor development and progression. These results suggest that laying hens can be used to generate information on the mechanism of spontaneous ovarian tumor-associated immuno-suppression and may lead to the development of antitumor immunotherapies and the testing of their efficacies. Recent progresses in the understanding of tumor-immune interactions have led to the successful development of a number of immunotherapeutic approaches. However, tumor escape from immune recognition is a significant barrier to the success of these immunotherapies. Although the process of escaping immune surveillance by tumors or suppression of antitumor immune response is not well understood, tumor cells, immune cells, and other stromal cells in the tumor surroundings have been reported to interact and create an immunosuppressive microenvironment through a variety of immunosuppressive factors [30] . Enhanced expression of ILT3 by few members of the immune system has been suggested as one of such immunosuppressive factors in the tumor microenvironment [31] . In the present study, in addition to immune cell-like cells, the epithelium of the ovarian tumors in laying hens also Figure 5 . Examples of immunoreactive ILT3 protein (A) or mRNA (B) expression in the homogenates of OSE and ovaries from normal hens or hens with OVCA by one-dimensional Western blot (WB) analysis and semiquantitative PCR, respectively. One-dimensional WB (A): Immunoreactive ILT3 protein of approximately 55-kDa molecular weight was detected in the 1) OSE extract from normal or ovarian tumors and 2) homogenates from different histologic subtypes of ovarian tumors at early stage of OVCA. Compared with the normal OSE or OSE from ovarian tumors at early stage, ILT3 protein expression was stronger in the OSE from hens at late-stage OVCA. Serous ovarian tumors at the early stage showed strong ILT3 staining followed by mucinous and endometrioid tumors. No ILT3 expression was detected in negative control in which protein sample was omitted. RT-PCR (B): mRNA expression by the OSE extract from normal or ovarian tumor and from different histologic subtypes of ovarian tumors at early and late stages of OVCA. Compared to the normal OSE, or OSE from ovarian tumor at early stage, a strong expression of ILT3 mRNA was observed in the OSE from hens with late-stage OVCA. Similarly, strong expression patterns were also observed for the homogenates of ovarian tumors at late stages than early stages irrespective of tumor subtypes. As observed in immunohistochemistry and immunoblot analysis, endometrioid tumors at early stage were weaker in ILT3 mRNA expression than their counterpart serous and mucinous tumors. No ILT3 mRNA expression was detected in the negative control in which mRNA sample was omitted. Figure 4 . Changes in the ovarian ILT3 expression are associated with ovarian tumor development and progression. The intensity of ILT3 staining is expressed as pixel values (mean ± SD) in a 20,000-μm 2 area of the ovarian stroma in normal ovaries or ovaries with tumor. Compared with normal hens, the intensities of the ILT3 staining were significantly greater in hens with early-stage OVCA (P < .001) and increased further in hens with late-stage OVCA irrespective of their tumor types. The intensity of ILT3 staining was significantly lower (P < .03) in hens with endometrioid OVCA than hens with serous OVCA. Significant differences were not observed in the intensity of ILT3 staining between the hens with serous and mucinous OVCA irrespective of their stages. Bars with different letters within the same group indicate significant differences in ILT3 staining intensity.
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expressed ILT3. Under normal physiological condition, ILT3 has been reported to be expressed selectively by professional antigen-presenting cells including monocytes, macrophages, and dendritic cells [32] . The expression of ILT3 on exposure to alloantigen-specific suppressor T cells or cytokines by nonprofessional antigen-presenting cells, like endothelial cells as well as tumor cells from chronic lymphocytic leukemia, was also reported previously [33, 34] . Thus, the present results suggest that ovarian tumors also express immunosuppressive ILT3 as reported for few other cancers.
In the present study, compared with normal hens, the intensity of the ILT3 expression was significantly high in hens with early-stage OVCA and increased further as the disease progressed to late stages, suggesting that changes in ILT3 expression may be associated with ovarian tumor development and progression. The presence of active antitumor immune responses against ovarian tumors at the early stage has been reported earlier [9] . However, despite the presence of an antitumor immune response, OVCAs in most cases, progress to late stages. Although the precise mechanisms of such immune escaping are not known, our results suggest that the enhanced expression of immune inhibitory receptor ILT3 by the ovarian tumors may contribute to the progression of OVCA.
The results of the present study suggest that the expression pattern of ILT3 varies with the different histologic subtypes of ovarian tumors. Significantly high ILT3 staining intensity was observed in serous compared with endometrioid ovarian tumors at early as well as late stages of OVCA. The specific reasons for higher ILT3 expression by serous OVCA are not known. It is possible that higher ILT3 expression will contribute to the faster progression of OVCA by imparting higher immune tolerance to tumors. Serous malignant ovarian tumors are considered aggressive tumors, and increased ILT3 expression may contribute to their faster progression. Similar observations in cancers of other organs were also reported previously [31, 34] . Thus, it is possible that ILT3 will contribute to ovarian tumor progression by suppressing antitumor immunity.
In the present study, a portion of the epithelial cells of the normal ovarian surface epithelium above the cortical developing follicles (not all epithelial cells) were positive for ILT3 expression albeit with lower intensity than the epithelium of ovarian tumors. Although the precise reason(s) for such expression is not known, it is possible that ILT3 expressed by surface epithelial cells near cortical follicles will protect them from immune cells by suppression of local antifollicular autoimmune response. Various structures in the developing follicles including the perivitelline membrane, granulosa and theca layers, as well as the degenerated cellular components of postovulatory follicles may appear as "foreign" to the circulating immune cells because these structures were not present during the evolution and maturation of the immune system.
Our understanding regarding the biology and the role of ILT3 in the context of OVCA is very limited, in part, because of the lack of an animal model that develops spontaneous OVCA. Because of the difficulty of detecting OVCA at an early stage, access to patient specimens to study and develop an effective antitumor immunotherapy is difficult and time consuming. Similarities between the spontaneous OVCA in humans and hens in histologic subtypes, risk factors (e.g., incessant ovulation), and expression of several molecular makers of OVCA represent a high probability that results obtained from this study may be translated to clinics. Furthermore, one of the most important advantages of this animal model relative to the possibilities of translating current findings to OVCA in humans is the ability to monitor hens by contrast enhanced ultrasound imaging using equipment and mechanical setting similar to those used in clinics [25, 26] . Thus, there will be less variation in imaging parameters between hens and humans because of the use of similar equipment. With the advancement in in vivo imaging technology, ligands that bind to the epithelial cells of the ovarian tumor are being developed to use as antitumor therapies, and their effectiveness in tumor ablation can be monitored in this animal model using contrast-enhanced ultrasound scanning [35] . Because the epithelial cells of the tumor in OVCA hens express ILT3, laying hens may be used to test the efficacy of anti-ILT3 drug by molecular-targeted ultrasound imaging of ovarian tissues. Thus, it will bring a significant change in the development of tumor specific therapeutics specially immunoenhancing drugs and lead to the development of treatment modalities for OVCA patients. Taken together, information on ILT3 expression and its association with OVCA progression will aid in the development of anti-ILT3 immunotherapies, which will lay the foundation for clinical studies and may ultimately lead to the development of effective therapies for the treatment of OVCA. Methods: Sera and ovarian tissues from 3-year-old laying hens were collected and processed for histopathologic, immunoassay, immunohistochemistry, immunoblotting, and molecular biological studies to determine the tissue expression and serum levels of IL-16. Samples were divided into 3 groups based on the diagnosis of the histopathologic ovarian tissue examination, namely, normal (healthy control, n = 81), early (n = 23 including 11 with microscopic OVCA), and late stages (n = 16) of OVCA.
Association of
Results: Serum levels of IL-16 were significantly higher in hens with microscopic, early, and late stages of OVCA than normal hens (P G 0.0001). The frequencies of IL-16 + cells in tumor-bearing ovaries were significantly higher than normal hens (P G 0.05). The expression of IL-16 protein and mRNA were stronger in tumor-bearing ovaries than normal ovaries. In addition to ovarian stroma, IL-16 was also expressed by the epithelial cells of the tumor in OVCA hens. Differences in serum levels and ovarian IL-16 expression were not significant among different histological subtypes of OVCA including serous, endometrioid, and mucinous. Similar to the serum levels and ovarian expression of IL-16, the densities of neoangiogenic microvessels were significantly higher in hens with tumor-bearing ovaries than normal hens.
Conclusions:
The results of the study suggest that changes in serum levels of IL-16 are associated with tumor development and TAN. Thus, serum IL-16 levels may be an indicator of ovarian TAN at the early stage of OVCA.
Key Words: Interleukin 16, Ovarian tumor, Tumor-associated neoangiogenesis, Ovarian cancer N onspecificity of symptoms at an early stage and the lack of an effective early detection test make ovarian cancer (OVCA) a fatal malignancy in women. 1 Circulating levels of CA-125 alone or in combination with transvaginal ultrasound scan did not substantially improve the diagnosis of earlystage OVCA. Thus, an effective early detection test for OVCA remains to be established. Similar to cancers of other organs, tumor-associated neoangiogenesis (TAN) is also an early event during ovarian tumor development, and it plays critical roles in tumor growth and progression. 2, 3 Thus, ovarian TAN vessels have the potential to be a target marker for early detection of OVCA. Doppler ultrasound scanning (DUS), a favored method for the detection of ovarian vascularity, cannot detect early ovarian TAN-related microvessels. Although vascular endothelial growth factor is a marker of TAN, it is not specific to OVCA. 4 Thus, for effective early detection of OVCA, either the current detection limit of DUS needs to be improved, or an effective serum marker of TAN needs to be explored.
Cytokines are reported to play putative roles in OVCA progression by enhancing tumor growth or metastasis or modulating the immune system. 5 Interleukin 16 (IL-16) is a cytokine involved in multiple immunopathobiological processes including chemotaxis of immune cells, 6 initiation of inflammatory responses, 7 and production of proangiogenic cytokines. 8 Interleukin 16 is produced mainly by members of the immune system. 6 Recently, IL-16 levels have been reported to be altered in association with several advancedstage solid tumors (breast, gastrointestinal, uterine renal/ bladder, and lung cancers), 9 hematologic malignancies, 10 and nonmalignant diseases including lupus and rheumatoid arthritis. An association between the serum levels of IL-16 and the early ovarian TAN has not yet been reported. If such an association exists, IL-16 may be used as a soluble marker to aid in vivo DUS detection of early ovarian TAN. Because it is difficult to identify patients at the early-stage OVCA, access to the patient's specimen remains a significant barrier to study existence of such an association.
Laying hens are the only widely available and easily accessible animals that develop OVCA spontaneously with a high incidence rate. 11 The histopathology and expression of several markers of OVCA in hens are similar to humans. 11, 12 As in humans, IL-16 in chicken is synthesized as a precursor protein (proYIL-16), with 49% to 52% identity to mammalian homologs. 13 Our goal was to determine whether the serum levels of IL-16 is associated with early-stage ovarian TAN in hens. We tested the hypothesis that serum levels of IL-16 are increased during ovarian tumor development and associated with early ovarian TAN.
MATERIALS AND METHODS
Animals
Commercial strains of 3-year-old white leghorn laying hens (Gallus domesticus) were maintained under standard poultry husbandry practices. The incidence of OVCA in hens of this age group is approximately 15% to 20% and is associated with low or complete cessation of egg laying. 14 
Hens
(n = 120) were selected on the basis of their egg-laying rates (normal or low) and transvaginal ultrasound as reported previously. 14 All experimental procedures were performed according to the Institutional Animal Care and Use CommitteeY approved protocol.
Tissue Collection and Processing
Serum Samples
Blood was obtained from brachial veins of all hens before they were killed, and the blood was centrifuged (1000g, 20 minutes), and serum samples were stored at j80-C.
Gross Ovarian Morphology and Histopathology
Ovarian pathology and tumor staging were performed by gross and histological examination as reported previously. 11 Each normal or tumor-bearing ovary was divided into 4 portions for protein extraction, total RNA collection, and paraffin and frozen embedding for routine histology and immunohistochemical studies as reported previously. 3 Normal ovarian surface epithelial cells or epithelial cells of the tumor in OVCA hens were collected similarly as reported earlier. 15 Samples were classified into 3 groups including normal-, early-, and late-stage OVCA based on the diagnosis of the histopathologic ovarian tissue examination as reported previously. 11
Preparation of Ovarian Specimen for Biochemical Analysis
Snap-frozen ovarian tissues as well as normal ovarian surface epithelial cells and epithelial cells of the tumor in OVCA hens were homogenized with a Polytron homogenizer (Brinkman Instruments, Westbury, NY) as reported previously 16 and centrifuged, and supernatant was collected; protein content of the extract was measured and stored at j80-C.
Immunoassay
Serum levels of IL-16 were determined by Chicken IL-16 Vetset ELISA Kit (Kingfisher Biotech, St Paul, MN) as per the manufacturer's instructions. Briefly, chicken IL-16 standards or serum samples were added to the wells precoated with antiYchicken IL-16 antibodies followed by the incubation with detection antibody and streptavidinYhorseradish peroxidase. Immunoreactions were developed by TMB substrate and stopped by 0.18 M sulfuric acid. The absorbance for each well was recorded by reading the plates at 450 nm in a plate reader (Thermomax; Molecular Devices, Sunnyvale, CA). A standard curve was generated by plotting the optical density values of the standards against their concentrations. Serum IL-16 levels were determined with reference to the standard curve as per manufacturer's instruction using a software program (Softmax Pro, version 1.2.0, software; Molecular Devices). All standards and serum samples were run in duplicate.
Immunohistochemistry
Immunohistochemical localizations of IL-16 + cells using antiYIL-16 (Kingfisher Biotech) and ovarian TAN vessels using antiYsmooth muscle actin (SMA) (Invitrogen, Carlsbad, CA) and antiY> v A3 integrins (CD51/CD61, clone 23C6; BioLegend, San Diego, CA) antibodies in normal or tumorbearing ovaries (n = 15 hens each for normal, early [including microscopic] and late stages) were performed as reported previously. 3 The number of hens for each group for immunohistochemical studies was determined based on the power analysis to achieve significant differences in the frequencies of immunopositive cells or microvessels among the 3 pathological groups. These hens were selected from each group randomly based on their reactivity in immunoassay. Double label immunostaining was performed to determine whether IL-16 is expressed by normal ovarian surface epithelium or epithelium of the tumor in OVCA hens. Briefly, frozen sections from normal or tumor-bearing ovaries were immunostained for cytokeratin (a marker of epithelial cell) using antiYcytokeratin 7 antibodies (this antibody was developed against OTN 11 ovarian carcinoma cell lines; Abcam Inc, Cambridge, MA) in the first step and antiYIL-16 antibodies in the second step. Cytokeratin-positive cells were visualized with DAB, and IL-16 + cells were detected by DAB with nickel chloride as reported earlier. 17 Sections were then counterstained with hematoxylin, dehydrated, and covered. In control staining, first antibody was replaced with normal mouse immunoglobulin G, and no immunopositive cell was found on the control slides.
Counting of Immunopositive Cells or Microvessels
The densities of IL-16 + cells, anti-SMA + , and anti-> v A 3 integrin + microvessels were counted from the normal ovarian or tumor stroma of hens using a light microscope attached to a digital imaging software (MicroSuite version 5; Olympus Corporation, Tokyo, Japan). Three sections per ovary were selected. In each section, 5 regions containing a high population of immunopositive microvessels or 5 random areas for IL-16 + cells were used. Frequencies of IL-16 + cells or microvessels in 20,000-Km 2 area were counted at a Â40 objective and Â10 ocular magnification as reported previously. 3, 18 The mean of these counts was considered as the number of immunopositive microvessels or IL-16 + cells in a 20,000-Km 2 area of a section. The mean of 3 sections was considered as the mean of immunopositive vessels or IL-16 + cells in normal or tumor-bearing ovaries. 3 
One-Dimensional Western Blot
Serum samples for Western blotting were selected randomly to represent normal (n = 5), early including microscopic (n = 12), and late stages (n = 12) of OVCA based on their immunoreactivity for IL-16 in immunoassay (enzyme-linked immunosorbent assay). Serum samples were filtered by acetonitrile and chloroform-methanol precipitation and tested by immunoblotting to confirm immunoreactions observed in immunoassay as reported earlier. 16 Similarly, ovarian expression of IL-16 was confirmed by using whole ovarian homogenates and normal ovarian surface epithelial cells or epithelial cells of the tumor in OVCA hens. Immunoreactions on the membrane were visualized as a chemiluminescence product (Super Dura West substrate; Pierce/Thermo Fisher, Rockford, IL), and the image was captured using a Chemidoc CRS (BioRad, Hercules, CA). Chicken recombinant IL-16 protein was used as standard in immunoblotting.
Reverse TranscriptionYPolymerase Chain Reaction
Interleukin 16 mRNA expression was assessed by semiquantitative reverse transcriptionYpolymerase chain reaction (PCR) as reported previously. 19 For reverse transcriptionY PCR analyses, serum and tissue samples from 5 normal, 12 early (including microscopic, 4 from each of the serous, endometrioid, and mucinous), and 12 late stages (4 from each of the serous, endometrioid, and mucinous) of OVCA hens were selected based on their reactivity in immunoassay, immunoblotting, and immunohistochemistry. Hen-specific IL-16 primers were designed by Oligoperfect Designer software (Invitrogen) using the IL-16 sequence from the NCBI (Gene-Bank NM_204352.3). The forward primer was 5-TCTCTGC TTTCCCCTGAA-GA, and the reverse primer was 5-GTC CATTGGGAAACACCT-TG located between exons 4 and 6.
A-Actin was used as the endogenous control with a forward primer of TGCGTGACATCAAGGAGAAG and a reverse primer of ATGCCAGGGTACATTGTGGT. The expected base pair size for the IL-16 amplicon was 199 base pairs and for A<actin was 300 base pairs. Polymerase chain reaction amplicons were visualized in a 3% agarose gel (Pierce/Thermo Fisher) in Tris-acetate-EDTA buffer and stained with ethidium bromide. The image was captured using a ChemiDoc XRS system (BioRad).
Statistical Analysis
The differences in the frequencies of IL-16 + cells and immunopositive microvessels among normal ovaries, tumorbearing ovaries in hens with early-stage and late-stage OVCA were assessed by analysis of variance, F tests, and the alternative nonparametric Kruskal-Wallis tests. Then pairwise comparisons between the groups (normal-, early-, and latestage OVCA) by 2-sample t tests and alternative Mann-Whitney tests were performed. All reported P values are 2<sided, and P G 0.05 was considered significant. Statistical analyses were performed with SPSS (PASW) version 18 software (IBM Inc, Armonk, NY).
RESULTS
Ovarian Morphologic and Histological Features
Gross Morphology
Hens with a fully functional ovary contained 5 to 6 developing preovulatory follicles (Fig. 1A) . Only 1 or 2 such follicles were present in the ovaries of low-laying healthy hens. In normal hens that stopped egg laying, ovaries and oviducts were regressed without any detectable abnormality. Solid tissue masses either limited to a small part or whole ovary and with or without ascites were observed in 12 hens and classified as hens with early-stage OVCA (Fig. 1B) . In 16 hens, tumor metastasized to abdominal organs with moderate 
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to profuse ascites and classified as hens with late-stage OVCA (Fig. 1C ).
Histopathology
Ovarian tumors in 28 hens that had solid mass limited to the ovaries (n = 12, early stage) or metastasized to other organs (n = 16, late stage) were confirmed by routine histology. However, tumor-associated microscopic features were also found during histological examinations in 11 additional hens (hens with microscopic OVCA) that had no grossly detectable solid mass in the ovary and were grouped in earlystage OVCA. Thus, a total of 23 (12 + 11) hens had early and FIGURE 1. Gross morphology and immunolocalization of IL-16 + cells in normal ovaries and ovaries with tumor in laying hens. AYC, Gross morphology of normal ovary or ovaries with tumors in hens. A, A normally laying hen ovary contains a hierarchy of multiple large preovulatory follicles with active oviduct. B, Ovarian cancer at an early stage in a laying hen. Tumor mass is limited to the ovary (shown in a dotted line), and the oviduct is atrophied. C, Late-stage OVCA in a laying hen. Tumor is metastasized to distant organs with accompanied profuse ascites (*). DYF, Interleukin 16Yexpressing cells in the stroma of a normal ovary or ovaries with tumors in laying hens. Frozen sections from ovaries shown in A to C were immunostained for IL-16Yexpressing cells. Cells expressing IL-16 are round or irregularly shaped and seen in the normal ovarian stroma as well as in the vicinity of tumors. D, Very few positive cells are seen in the stroma of normal ovary. E and F, Interleukin 16 expression in early (E) and late (F) stages of OVCA in laying hens. A number of epithelial cells (not all) of the tumor in the ovaries were also positive for IL-16 expression (EYF). Compared with normal ovary (D), more IL-16 + cells are seen in the stroma of the ovaries with tumor (EYF) in OVCA hens. G-I, Expression of IL-16 by ovarian epithelium in hens with or without OVCA. Frozen sections were immunostained for cytokeratin 7 (a specific marker for epithelial cell) in the first step to confirm ovarian epithelial cells and for IL-16 in the second step using DAB and DAB and nickel chloride, respectively. 16 had late stage of OVCA, whereas 81 hens were normal. Tumors were typed as serous (n = 17), endometrioid (n = 12), mucinous (n = 8), and clear cell (n = 1) as well as mixed (n = 1, seromucinous) as reported previously. 11 Tissue Expression and Serum Levels of IL-16
Immunohistochemical Detection of Ovarian IL-16 Expression
Rounded (T lymphocyteYlike) to irregularly shaped (macrophage-like appearances) IL-16 + cells were detected in the stroma of normal or tumor-bearing ovaries and in the tumor vicinity including spaces between tumor glands ( Figs. 1DYF) . A number of epithelial cells (not all) in normal or tumor glands were also positive for IL-16 (Figs. 1DYF) , which was confirmed by double immunostaining for IL-16 together with cytokeratin (Figs. 1GYI) . The frequencies of IL-16 + cells in the stroma of tumor-bearing ovaries in hens with early-stage (mean, 15.88 [SD, 3.33] cells/20,000-Km 2 area) and late-stage (19.5 [SD, 4.90 ] cells/20,000-Km 2 area) OVCA were significantly (P G 0.05) higher than in the ovarian stroma of normal hens (5.24 [SD, 1.38] cells/20,000-Km 2 area). Thus, epithelial cells in normal ovaries or tumor-bearing ovaries also express IL-16.
Immunoassay for Serum IL-16 Levels
Mean concentration of serum IL-16 was 259.91 (SD, 71.90) pg/mL in normal hens (n = 50). Compared with normal hens, the mean concentration of serum IL-16 was significantly higher (P G 0.0001) in hens with microscopic OVCA (531.85 [SD, 193 .77] pg/mL) and increased further in hens with early (739.55 [SD, 148.75] pg/mL) and late stages (767.04 [SD, 264.37] pg/mL) of OVCA (Fig. 2) . Although compared with hens with microscopic OVCA, serum IL-16 levels were significantly higher in hens with early (P G 0.009) and late stages (P G 0.004) of OVCA, differences in serum IL-16 levels were not significant between the early-and latestage OVCA as well as among the different histological subtypes of OVCA.
Immunoblotting for IL-16 Protein in Serum Samples and Ovarian Tissues
Immunoreactivity of serum IL-16 detected by immunoassay was confirmed with immunoblotting using serum samples from selected hens representative of each group including normal-, early-, and late-stage OVCA. As expected, a band at approximately 15 to 18 kd was detected in recombinant IL-16 samples (data not shown), whereas a band of approximately 60 to 65 kd (equivalent to the homotetramer of recombinant IL-16 peptide) was detected in the serum from normal hens or hens with OVCA (Fig. 3A) .
Expression of ovarian IL-16 was also confirmed by immunoblotting using ovarian epithelium or whole ovarian homogenates from normal hens or hens with OVCA. Interleukin 16 protein from whole ovarian homogenates in hens with OVCA showed moderate to intense immunoreactivity ( Fig. 3B) . In contrast, either a very weak or no immunoreactive band was seen for whole ovarian homogenates from healthy hens. Similarly, stronger IL-16 immunoreactivity was observed for the epithelial cells of the tumor in OVCA hens than that of normal ovarian surface epithelial cells (Fig. 3B) . These results confirm the immunohistochemical observation that ovarian surface epithelial cells in normal hens and epithelial cells of the tumor in OVCA hens may be a source of IL-16 proteins in hens.
Expression of IL-16 Messenger RNA
Interleukin 16 messenger RNA (mRNA) expression confirmed the observed variations in serum IL-16 levels and ovarian IL-16 expression among normal and OVCA hens. Hens with ovarian tumors showed strong amplification signal for IL-16 ( Fig. 3C) and differences were not observed in IL-16 mRNA expression among different histological subtypes of OVCA. In contrast, IL-16 mRNA expression was weak for whole ovarian homogenates from normal hens. Similar patterns were also observed for surface epithelial cells of the normal ovaries or epithelial cells of the tumor in OVCA hens. Overall, compared with normal hens, strong amplification of IL-16 mRNA was observed in OVCA hens as observed for immunoreactivities in immunoassay and immunoblotting. 
Expression of Angiogenic Markers
Immunopositive microvessels (anti-SMA + and anti-> v A 3 integrin + ) were detected in both normal ovaries (n = 15) and ovarian tumors (n = 15 hens each for early-and late-stage OVCA). In normal hens, the wall of immunopositive ovarian vessels, in most cases, was thick, complete, and continuous with intense staining. A few microvessels were also seen in the theca layers of the follicles of normal hens, indicating active sites of physiological angiogenesis associated with follicular development (Fig. 4A) . In contrast, most of the immunopositive microvessels in tumor-bearing ovaries were leaky, discontinuous, or incomplete with thin vessel walls. In OVCA hens, more immunopositive microvessels were seen in tumor vicinity and in the stroma adjacent to the tumors (Figs. 4B, C) . The frequencies of immunopositive microvessels were significantly (P G 0.0001) higher (12.77 [SD, 2.19] anti-SMA and 6.77 [SD, 3.00] antiY> v A 3 integrins + microvessels in 20,000-Km 2 area of tissues) in early-stage OVCA hens than normal hens (5.06 [SD, 1.46] anti-SMA and 2.7 [SD, 0.84] antiY> v A 3 integrins + microvessels in 20,000-Km 2 area of tissues) (Fig. 5 ). Their frequencies increased further (P G 0.0001) in hens with late-stage OVCA (19.39 [SD, 1.95] anti-SMA and 9.97 [SD, 1.65] antiY> v A 3 integrins + microvessels in 20,000-Km 2 area of tissues). 
DISCUSSION
This is the first report that serum levels and tissue expression of IL-16 increase significantly in association with the development and progression of ovarian TAN in laying hens, a preclinical animal model of spontaneous OVCA. These results suggest that serum IL-16 levels may be a potential indicator of early-stage ovarian TAN and may be useful in combination with conventional markers including vascular endothelial growth factor to detect ovarian TAN.
Precise molecular mechanism of the initiation and regulation of ovarian TAN is not well understood. Involvement of several cytokines and growth factors in the development of TAN has been reported. 5 Interleukin 16 was reported to be involved 9 in lymphoid and ovarian malignancies, 5,10 but none of these reports examined its association with early stages of malignancies. As in humans, 5 the present study showed that IL-16 in hen serum and ovarian tissues also exists in the active homotetramer form. In this study, compared with normal hens, serum levels and tissue expression of IL<16 increased significantly in OVCA hens including microscopic OVCA. The reason(s) for this increase in IL-16 levels in OVCA hens is not known. However, this study suggests that tumor-associated increase in IL-16 level can be detected in serum even before the tumor becomes detectable by TUVS (microscopic OVCA). Furthermore, this increase was correlated with the increased density of TANrelated microvessels. Thus, increased serum IL-16 levels, as observed in hens with early-stage OVCA, may represent an effective serum indicator of early-stage ovarian TAN.
The sources of serum IL- 16 are not yet fully known, and published reports are very limited. 20, 21 In addition to the immune cells, IL-16 has been reported to be secreted by bronchial epithelium in humans. 20, 21 In this study, normal ovarian surface epithelial cells and epithelial cells of the tumor in OVCA hens were positive for IL-16 expression, suggesting that these tissues may also be a source of serum IL-16. Double immunohistochemical labeling showed the expression of IL-16 by the surface epithelial cells of the normal ovaries and epithelial cells of the tumor in OVCA hens, which was further supported by IL-16 protein and mRNA expression. These results are consistent with the previous report that bronchial and tracheal epithelial cells also secrete IL-16. 21 Thus, normal ovarian surface epithelial cells and epithelial cells of the tumor in OVCA hens were also a source of IL-16, and secretion of IL-16 by the epithelial cells of the tumor may be one of the reasons for elevated serum IL-16 levels in OVCA hens including those with microscopic OVCA.
Although the physiological significance of epithelial cellYderived IL-16 in the pathogenesis of OVCA is not clear, it is possible that IL-16 may be involved in the development and progression of OVCA. First, the positive correlation between the increase in IL-16 levels and the frequency of TAN vessels in OVCA hens suggests a proangiogenic role of IL-16 in the progression of ovarian TAN. A proangiogenic role of IL-16 has also been reported in humans. 8 Second, increased expression of IL-16 by epithelial cells of the tumor in OVCA hens and increased levels of serum IL-16 in hens with microscopic OVCA even before the tumor becomes detectable suggest that serum IL-16 levels may also be an indicator of malignant ovarian transformation. Thus, it is possible that IL-16 secreted by the epithelial cells of the tumor in OVCA hens may contribute to ovarian TAN required for tumor growth and may be an effective indicator of ovarian tumorigenesis.
Because of the difficulty of detecting OVCA at an early stage, access to patient specimens to study and develop an early detection test is difficult and time consuming. Because of the similarities between the spontaneous OVCA in humans and hens including histological subtypes, molecular pathways, risk factors (eg, incessant ovulation), and expression of several molecular markers of OVCA, there is a high probability that the results obtained from the OVCA studies in laying hens may be translated to clinics. Moreover, one of the most important advantages relative to the translationalities of the current findings is that OVCA development in FIGURE 5 . Changes in the ovarian IL-16 expression are associated with the increase in the frequencies of ovarian tumor-associated microvessels. The frequencies of immunopositive IL-16 cells or microvessels are expressed as the mean (SD) in 20,000-Km 2 area. As compared with normal hens (n = 15 hens), the frequencies of the IL-16 + cells as well as angiogenic microvessels were significantly increased in hens with OVCA (n = 15 hens each for early including microscopic and late stages of OVCA). The increase in the frequency of ovarian IL-16Yexpressing cells is associated with the increase in the frequencies of SMA and > v A 3 integrinYexpressing microvessels. Bars with different letters indicate significant differences (P G 0.001) among different pathological categories in IL-16 + cell, SMA + , or > v A 3 integrins expressing microvessel groups. 
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hens can be monitored by contrast-enhanced ultrasound imaging using equipment and mechanical setting similarly used in clinics. 3, 14 Thus, there will be least variation on imaging parameters between hens and humans because of the equipment. With the advancement in in vivo imaging technology, ligands that bind to the epithelial cells of the tumor in OVCA hens are being developed to use in conjunction with microbubbles for contrast-enhanced ultrasound scanning to facilitate early OVCA detection. 18 As the epithelial cells of the tumor in OVCA hens express IL-16, it may be used as a target for contrast-enhanced ultrasound imaging and will increase the sensitivity of ultrasound scanning detection of OVCA together with serum levels of IL-16. Thus, it will bring a significant change in imaging paradigms and improve the specificity of ultrasound scanning. It will also be possible to determine the time between the tumor-associated elevation of IL-16 in serum and the earliest detection of tumor by contrast-enhanced ultrasound scanning. This information will enable to detect OVCA at an early stage and lead to the development treatment modalities for OVCA patients. In addition, current findings will also be useful in developing ovarian tumor-associated antiYIL-16 therapies and can be tested in laying hens. Taken together, information on the association of serum and tissue expression of IL-16 with the early detection of OVCA and the potential development of antiYIL-16Ybased therapies in laying hens will establish the foundation for clinical studies that may ultimately lead to the development of an effective diagnostic test and therapies for OVCA at an early stage.
One of the limitations of the present study is that it did not examine the serum levels and tissue expression of IL-16 in ovarian benign tumors. Thus, exclusion of ovarian benign tumors from the study may limit the translational significance of the findings that serum IL-16 levels may be used as a biomarker for early detection of OVCA. However, serum levels of IL-16 were reported to be significantly higher in patients with prostate cancer than patients with benign prostatic hyperplasia. 22 Therefore, to evaluate the effectiveness of serum IL-16 as a biomarker for early OVCA detection or as a target for imaging of ovarian tumors in patients with early-stage OVCA, present observations need to extend to the investigations on benign ovarian tumors and other benign conditions associated with de novo angiogenesis or IL-16 elevations.
The laying hen is a suitable model to study the role of IL-16 in the pathogenesis of OVCA. With the emergence of newer in vivo imaging technologies, effective targets in the tumor in OVCA hens are being identified to be detected by targeted contrast-enhanced ultrasound imaging to facilitate early OVCA detection. As the epithelial cells of the tumor in OVCA hen express IL-16, these cells may be used as a target for such molecular targeted ultrasound imaging. Thus, serum IL-16 levels together with ultrasound imaging of ovarian tumor-associated IL-16 expression may constitute an effective test for early OVCA. Laying hens are also a suitable model for the development of ultrasound contrast agents for OVCA detection. 18 Finally, the laying hen may also be used to test the efficacy of antiYIL-16 therapies for effective prevention of ovarian TAN. Background: Because of the lack of an early detection test, ovarian cancer (OVCA) remains a lethal malignancy of women. OVCA differs from other malignancies in its specific dissemination pattern that the tumor typically spreads in a diffuse intra-pelvic and abdominal manner. Thus tumor microenvironment plays an important role in tumor dissemination and suppression of anti-tumor immunity is a hallmark of tumor progression. Although the precise mechanism of immune evasion by the tumor is not known, expression of death receptor 6 (DR6) has been suggested to be associated with tumor progression in several malignancies. DR6 is a member of the TNF receptor superfamily and a regulator of immune function. Expression of DR6 by ovarian tumors is unknown. Access to patients at early stage OVCA is very difficult. Laying hens develop OVCA spontaneously with histopathology similar to humans. Objectives: The goal of the present study was to determine whether DR6 is expressed by ovarian tumors at early stage and to examine whether DR6 expression is associated with OVCA tumor progression in the laying hen model of human OVCA. Materials and Methods: 3 years old normal, low or stopped egglaying hens were scanned by ultrasound, sera were collected, hens were euthanized and ovarian tissues were processed for paraffin and frozen sections, immunoblotting and mRNA extraction. Stages of OVCA were confirmed at gross morphology and routine histology. Samples were divided into 3 groups: normal (control), early and late stages of OVCA. Sera were tested for DR6 levels by ELISA and confirmed by 2D-Western blot (WB).
Expression of DR6 by normal and tumor ovaries was examined by immunohistochemistry (IHC), WB and RT-PCR. Results: DR6 was expressed by the epithelium of the ovarian tumor and angiogenic microvessels in the tumor stroma. The population of DR6+ microvessels and serum levels of DR6 was significantly higher in hens with ovarian tumors than the normal hens. Immunoblotting and gene expression analysis confirmed IHC observations. There was a significant increase in DR6 expression in hens with early stage OVCA (including microscopic tumor) suggesting that serum DR6 may be a potential indicator of ovarian tumors at very early stage. The frequencies of DR6+ cells were significantly higher in hens with late stage OVCA than early stage suggesting that DR6 may be involved in ovarian tumor development and progression in laying hens. Conclusion: For the first time, this study showed that epithelial cells in ovarian tumors express DR6 and results suggest that changes in serum levels as well as tissue expression of DR6 are associated with tumor initiation and progression. Thus serum DR6 may be useful as a surrogate maker of OVCA, target for anti-tumor immunotherapy as well as molecular imaging. This study will provide a foundation for a clinical study. Support: DOD (OC#093303), NCI-POCRC (P50 CA83636) and the Elmer Sylvia and Sramek Foundation. 
